11 completed, 7 unknown, 1 active not recruiting, 1 enrolling by invitation. 20 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 11, Unknown 7, Active not recruiting 1, Enrolling by invitation 1 |
| Phase 1 | 5 | Completed 2, Unknown 2, Active not recruiting 1 |
| Phase 3 | 2 | Completed 2 |
Follow Safety Issues: new trials by email Literature Review of Safety Issues trials Research Report on Safety Issues
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer mfolfox6 and hlx04 regimen and Serplulimab, mfolfox6 and hlx04 regimen - Efficacy, Self, Safety Issues | Phase 2 | Unknown | Sir Run Run Shaw Hospital | 72 | 2024-07-01 | 2024-07-09 |
| Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL Polatuzumab Vedotin, Zanubrutinib, Rituximab - Effects of Chemotherapy, Safety Issues | Phase 2 | Enrolling by invitation | The First Affiliated Hospital of Soochow University | 20 | 2023-07-01 | 2024-06-21 |
| Is Local Injection of Mesenchymal Stem Cells After Endoscopic Dilation Safe and Does it Improve the Outcome of Intestinal Stricture in Patients With Crohn's Disease? Mesenchymal Stem Cells, Comparative placebo - Safety Issues, Efficacy | Phase 2 | Unknown | Centre Hospitalier Universitaire de Liege | 50 | 2023-06-06 | 2024-03-19 |
| Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma low dose nivolumab in combination with AVD - Safety Issues, Efficacy, Self | Phase 2 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 16 | 2023-02-13 | 2023-03-16 |
| ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection 15 mg ADC189, 45 mg ADC189, Placebo - Safety Issues, Effect of Drug | Phase 2 / Phase 3 | Completed | Jiaxing AnDiCon Biotech Co.,Ltd | 749 | 2022-12-07 | 2025-01-21 |
| Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis Proglumide, Placebo - Safety Issues, Pain | Phase 1 / Phase 2 | Active not recruiting | Georgetown University | 32 | 2022-11-17 | 2026-08-05 |
| Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma Sintilimab 200mg+MB07133 600mg - Safety Issues, Efficacy | Phase 1 / Phase 2 | Unknown | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 39 | 2022-01-18 | 2023-11-21 |
| SEPSIS: L. Plantarum Trial Synbiotic, Probiotic, Placebo - Microbial Colonization, Tolerance | Phase 2 | Completed | The Hospital for Sick Children | 519 | 2022-01-07 | 2023-04-13 |
| Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors IPG7236 - Safety Issues, Tolerability | Phase 1 / Phase 2 | Completed | Nanjing Immunophage Biotech Co., Ltd | 34 | 2021-11-15 | 2026-07-08 |
| ChulaCov19 Vaccine in Healthy Adults ChulaCov19 vaccine, Placebo - COVID-19 Vaccine, Safety Issues | Phase 1 / Phase 2 | Completed | Chulalongkorn University | 192 | 2021-05-03 | 2023-02-09 |
| Tofacitinib as a GC Sparing Agent for Polymyalgia Rheumatica Tofacitinib 5 MG - Polymyalgia Rheumatica, Effect of Drug | Phase 2 | Completed | RenJi Hospital | 14 | 2021-01-01 | 2022-09-15 |
| TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss TQB3525 - Safety Issues, Efficacy, Self | Phase 1 / Phase 2 | Unknown | Peking University People's Hospital | 29 | 2020-10-01 | 2020-12-31 |
| MB07133 for the Treatment of Patients With Unresectable Hepatocellular Carcinoma MB07133 - Safety Issues, Effect of Drug | Phase 2 | Unknown | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 91 | 2020-01-17 | 2023-11-21 |
| Trial of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy Béfizal - Safety Issues, Efficacy, Self | Phase 2 / Phase 3 | Completed | Hôpital Necker-Enfants Malades | 14 | 2019-03-26 | 2023-09-22 |
| Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants Vi-DT Vaccine, Vi Polysaccharide Vaccine, IPV Vaccine - Safety Issues, Immunogenicity | Phase 2 | Completed | PT Bio Farma | 600 | 2018-07-16 | 2020-02-20 |
| Autologous Cord Blood Cells for Prevention of BPD in Preterm Autologous Umbilical Cord Blood Mononuclear Cells infusion Therapy, 0.9% Sodiun Chloride - Safety Issues, BPD - Bronchopulmonary Dysplasia | Phase 2 | Completed | yangjie | 62 | 2018-07-01 | 2020-06-02 |
| Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer Bevacizumab - Metastatic Triple Negative Breast Cancer, Safety Issues | Phase 2 | Completed | Assiut University | 54 | 2018-07-01 | 2021-03-09 |
| Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer Atezolizumab - Safety Issues | Phase 2 | Unknown | McGill University Health Centre/Research Institute of the McGill University Health Centre | 25 | 2018-05-01 | 2018-08-13 |
| Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population Quadrivalent Influenza Vaccine, Trivalent Influenza Vaccine - Safety Issues | Phase 2 | Completed | PT Bio Farma | 810 | 2017-11-21 | 2019-04-02 |
| Remifemin Preventing the Climacteric Symptoms in Breast Cancer Remifemin - Effect of Drugs, Safety Issues | Phase 2 | Completed | Zhejiang Cancer Hospital | 85 | 2017-01-04 | 2018-07-06 |
Breast Neoplasms (1) · Bronchopulmonary Dysplasia (1) · COVID-19 (1) · Chondrosarcoma (1) · Colonic Neoplasms (1) · Communicable Diseases (1) · Diabetes Mellitus (1) · Hodgkin Disease (1) · Osteosarcoma (1) · Pain (1) · Pancreatitis (1) · Perinatal Death (1) · Polymyalgia Rheumatica (1) · Sarcoma, Ewing (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (5) · Neoplasms by Site (3) · Pathological Conditions, Signs and Symptoms (3) · Skin and Connective Tissue Diseases (3) · Breast Diseases (2) · Digestive System Diseases (2) · Infections (2) · Lung Diseases (2) · Neoplasms by Histologic Type (2) · Pathologic Processes (2) · Respiratory Tract Diseases (2) · Skin Diseases (2) · Breast Neoplasms (1) · Colonic Diseases (1) · Colorectal Neoplasms (1)
4-amino-1-(5-O-(2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl)arabinofuranosyl)-2(1H)-pyrimidinone (2) · Prednisone (2) · Bevacizumab (1) · Bezafibrate (1) · ChulaCov19 vaccine (1) · Cyclophosphamide (1) · Doxorubicin (1) · Influenza Vaccines (1) · Nivolumab (1) · Probiotics (1) · Proglumide (1) · Remifemin (1) · Rituximab (1) · Synbiotics (1) · TQ-B3525 (1)
PT Bio Farma (2) · Xi'an Xintong Pharmaceutical Research Co.,Ltd. (2) · Assiut University (1) · Centre Hospitalier Universitaire de Liege (1) · Chulalongkorn University (1) · Georgetown University (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · Hôpital Necker-Enfants Malades (1) · Jiaxing AnDiCon Biotech Co.,Ltd (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Nanjing Immunophage Biotech Co., Ltd (1) · Peking University People's Hospital (1) · RenJi Hospital (1) · Sir Run Run Shaw Hospital (1) · The First Affiliated Hospital of Soochow University (1)
China (10) · Indonesia (2) · United States (2) · Bangladesh (1) · Belgium (1) · Canada (1) · Egypt (1) · France (1) · Mexico (1) · Thailand (1)
Bernie Endyarni, MD (1) · Daniel Roth, MD, PhD (1) · Dominique Bremond Gignac, MD PhD (1) · Jie Yang, PHD (1) · Jill P Smith, MD (1) · Kiat Ruxrungtham, MD (1) · Meita Dhamayanti (1) · Perla R Colunga Pedraza, MD (1) · Ting Li, MD (1) · Wassim Kassouf, MD (1) · Wei Guo, Ph.D and M.D. (1) · Xingfei Yu (1)
PMID 21383283, PMID 22415477, PMID 27501767, PMID 28434018, PMID 30935866, PMID 31112476, PMID 31598921, PMID 31862195, PMID 32004693, PMID 32352505, PMID 32786092, PMID 33059607, PMID 33062947, PMID 34407054, PMID 36604153, PMID 37616221, PMID 38287068, PMID 38297337, PMID 38794273, PMID 39992135, PMID 40089214, PMID 42066676